Literature DB >> 2488025

Ocular side effects of the lipid-lowering drug simvastatin? A one year follow-up.

W Behrens-Baumann1, A Morawietz, J Thiery, C Creutzfeldt, D Seidel.   

Abstract

Simvastatin, a new HMG-CoA-reductase inhibitor, was administered to 27 patients for a period of one year. This drug caused a sustained decrease in total plasma- and LDL-cholesterol. No development of cataracts could be observed during this one year follow-up.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2488025

Source DB:  PubMed          Journal:  Lens Eye Toxic Res        ISSN： 1042-6922


  4 in total

1.  Data mining in pharmacovigilance: lessons from phantom ships.

Authors:  Manfred Hauben; Lester Reich; Eugène P Van Puijenbroek; Charles M Gerrits; Vaishali K Patadia
Journal:  Eur J Clin Pharmacol       Date:  2006-08-03       Impact factor: 2.953

2.  Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia.

Authors:  J Thiery; C Creutzfeldt; W Creutzfeldt; A K Walli; D Seidel
Journal:  Klin Wochenschr       Date:  1990-08-17

3.  Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group.

Authors:  M L Harris; A J Bron; N A Brown; A C Keech; K R Wallendszus; J M Armitage; S MacMahon; G Snibson; R Collins
Journal:  Br J Ophthalmol       Date:  1995-11       Impact factor: 4.638

Review 4.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.